CompletedNot Applicable

Pharmacogenetic Study of Different Hormone Therapies in Recent Menopause Women

Brazil90 participantsStarted 2007-03

Plain-language summary

This is cross-over, randomized clinical trial, with objective to evaluate the effects of low-dose oral hormone therapy and non-oral hormone therapy on endothelial function markers (fibrinogen, von Willebrand factor, c-reactive protein), natriuretic peptide and on anthropometric, metabolic and hormonal variables in early and healthy postmenopausal women and analyzing polymorphisms in the estrogen receptor gene and FTO polymorphisms Patients will be randomized to receive oral hormone treatment or non-oral hormone treatment The investigators hypothesis is that a different genotypes in the receptor estrogen gene and FTO may have an influences on treatment response in metabolic markers and cardiovascular risk

Who can participate

Age range42 Years – 58 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * last menstrual period between 6 months and 3 years before the beginning of the study plus FSH levels higher than 35 IU/L; * age between 42 and 58 years; * no use of any medication known to interfere with hormonal, glucose, or lipoprotein levels in the past 3 months; * no use of steroidal or no steroidal anti-inflammatory drugs in the last 15 days. Exclusion criteria: * patients with diabetes, * previous hysterectomy, * endometrial thickness \>0.5cm, * history of cancer, * thromboembolism, or * established cardiovascular disease

What they're measuring

Polymorphisms of estrogen receptor

Timeframe: six months

Trial details

NCT IDNCT01432028

SponsorDenusa Wiltgen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-04

View on ClinicalTrials.gov More Postmenopause trials